Immunome heads into its August 13 earnings report with a clear tension: the stock is drifting higher while nearly every insider who can sell, is selling.
The insider activity is the standout signal. Over the past 90 days, net insider selling has topped $14 million, with a C-suite executive, Horn, A. Kinney, offloading roughly $2.3 million in shares in early August alone. The Chief Medical Officer added further sales in July, and a board-linked venture firm has been selling steadily across multiple dates. None of these trades carry high individual significance scores, but the pattern is consistent and accelerating as the stock climbs — now up 12% in a month to $26.25.
Short interest is elevated but losing momentum, which tells a different story from the insider activity. At 18.2% of the free float, bears still hold a meaningful position. But that number has fallen roughly 8.7% over the past month, meaning shorts have been trimming rather than pressing. Borrow is remarkably cheap at just 0.54%, and availability is loose — nearly four shares available to borrow for every one already lent out — so there is no squeeze pressure building in the lending market. The ORTEX short score has also edged lower over the past week, from around 72.9 to 70.6, consistent with a modest short-covering trend. Options positioning has turned incrementally more cautious into the print, with the put/call ratio at 0.43 compared to a 20-day average of 0.34, though the move is mild — roughly one standard deviation above the norm — and well short of the 52-week high of 0.89.
Analysts are broadly constructive but have not been aggressive recently. The consensus price target near $35.85 implies roughly 37% upside from current levels, though the most recent reiterations have been from Wedbush holding at $31 — below the current mean — and no firm has upgraded or raised its target since late May. Bulls point to the depth of the oncology pipeline, particularly lead candidates varegacestat and IM-1021, and the promise of FDA catalyst timelines stretching into 2027. Bears flag the binary nature of those catalysts, execution risk in clinical trials, and competition from larger players. The two most recent earnings reactions have been negative — the stock fell roughly 3.5% in a day and 14.5% over five days after the May 2026 print — adding a specific caution to the setup.
Institutional ownership remains concentrated and mostly patient, with T. Rowe Price at nearly 17% of shares and Wellington adding close to 3.8 million shares as of June 30. But that institutional conviction stands in contrast to the insider selling trend, and Thursday's print is ultimately a test of whether the pipeline narrative can hold up against a backdrop of consistent insider distribution at every price step higher.
See the live data behind this article on ORTEX.
Open IMNM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
